Related Experiment Video

Updated: Aug 19, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Beta-blockade by sotalol in early myocardial infarction decreases ventricular arrhythmias without increasing left

E A Lloyd1, R G Charles, G D Gordon

  • 1Cardiac Clinic, Groote Schuur Hospital, Cape Town.

South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
|July 2, 1988
PubMed

Insights

Intravenous sotalol in acute myocardial infarction (AMI) safely reduced heart rate and ventricular tachycardia without increasing left ventricular (LV) volume. This study demonstrates sotalol

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Early beta-blockade in acute myocardial infarction (AMI) offers potential benefits like anti-arrhythmic effects and infarct size limitation.
  • However, the specific hemodynamic effects of intravenous beta-blockers in AMI require further characterization.

Purpose of the Study:

  • To investigate the hemodynamic effects and impact on left ventricular (LV) volumes of intravenous sotalol in patients with AMI.
  • To assess the safety and efficacy of sotalol in managing arrhythmias and infarct size.

Main Methods:

  • A randomized controlled trial involving 30 patients with AMI, commencing treatment 6 hours post-chest pain onset.
  • Patients received either a control or sotalol therapy (40 mg escalating to 120 mg, then maximal tolerated dose every 6 hours for 72 hours).
  • Systemic hemodynamics, pulmonary wedge pressure, enzymatic infarct size, ventricular tachycardia incidence, and LV volumes (via radionuclide techniques) were measured.

Main Results:

  • Sotalol significantly reduced heart rate and mean blood pressure.
  • No significant increase in pulmonary wedge pressure or enzymatic infarct size was observed.
  • A notable decrease in the incidence of ventricular tachycardia was recorded (P < 0.001).
  • Crucially, radionuclide assessment showed no increase in left ventricular (LV) volume.

Conclusions:

  • Intravenous sotalol effectively managed hemodynamic parameters and reduced ventricular tachycardia in AMI patients.
  • Sotalol demonstrated a favorable safety profile, avoiding adverse effects like LV dilatation.
  • These findings support the safe use of intravenous sotalol for its beneficial effects in acute myocardial infarction.

More Related Videos

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery04:48

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery

Published on: November 28, 2018

Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System08:01

Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System

Published on: June 11, 2020

Related Concept Videos

Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...